Keisuke Sunakawa
About
In The Last Decade
Keisuke Sunakawa
169 papers receiving 2.5k citations
Peers
Comparison fields: 5 of 106
- Epidemiology 1.7k
- Microbiology 1.0k
- Infectious Diseases 642
- Public Health, Environmental and Occupational Health 481
- Molecular Medicine 468
Countries citing papers authored by Keisuke Sunakawa
This map shows the geographic impact of Keisuke Sunakawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keisuke Sunakawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keisuke Sunakawa more than expected).
Fields of papers citing papers by Keisuke Sunakawa
This network shows the impact of papers produced by Keisuke Sunakawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keisuke Sunakawa. The network helps show where Keisuke Sunakawa may publish in the future.
Co-authorship network of co-authors of Keisuke Sunakawa
This figure shows the co-authorship network connecting the top 25 collaborators of Keisuke Sunakawa. A scholar is included among the top collaborators of Keisuke Sunakawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keisuke Sunakawa. Keisuke Sunakawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Clinical Efficacy of Tebipenem Pivoxil Treatment in Children with Pneumonia Classified According to Guideline-based Severity | 1 |
| 2 | Population pharmacokinetics and pharmacodynamics of tosufloxacin granules in pediatric infectious diseases | 4 |
| 3 | An open clinical study of tebipenem pivoxil in children with acute otitis media and acute upper respiratory tract infection (phase II) | 1 |
| 4 | An open clinical study of tebipenem pivoxil in children with bacterial pneumonia | 3 |
| 5 | Survey on once-daily therapy with ceftriaxone for pediatric bacterial infections | 1 |
| 6 | 1 | |
| 7 | 2 | |
| 8 | 6 | |
| 9 | Population pharmacokinetics of arbekacin in pediatric patients. | 2 |
| 10 | Epidemiology of Streptococcus pneumoniae isolates from patients with meningitis between 1993 and 2002 | 2 |
| 11 | 1 | |
| 12 | 1 | |
| 13 | A mouse model of Escherichia coli .O157: H7 infection for evaluation of antibacterial drugs - In vivo release of verotoxins and toxic effect on mice | 3 |
| 14 | Clinical summary of intravenous use of vancomycin hydrochloride for severe infection caused by methicillin-resistant Staphylococcus aureus | 7 |
| 15 | [Pharmacokinetic and bacteriological studies on sulbactam/ampicillin in the field of pediatrics]. | 2 |
| 16 | 3 | |
| 17 | From the Teacher to the Top. | 2 |
| 18 | Fundamental And Clinical Evaluation of 9,3”-Diacetylmidecamycin in Pediatric Field | 1 |
| 19 | 2 | |
| 20 | 1 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.